On June 25, 2025, ARS Pharmaceuticals held its Annual Meeting where stockholders elected four Class II directors and ratified Ernst & Young LLP as the independent auditor for 2025. Voting results included 64.9M votes for Richard Lowenthal and 77.3M votes for the accounting firm, with other directors also receiving favorable votes.